Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01055899 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01055899 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT01055899, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will test the safety and tolerability (how the body reacts to the drug) of REGN88 and placebo (an inactive substance that contains no medicine) in patients with Rheumatoid Arthritis.
Interventions
- BIOLOGICAL REGN88
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01055899
The ClinicalTrials.gov registry entry for NCT01055899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REGN88 is the first listed.
NCT01055899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01055899 about?
NCT01055899 is a clinical study titled "Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis". This study will test the safety and tolerability (how the body reacts to the drug) of REGN88 and placebo (an inactive substance that contains no medicine) in patients with Rheumatoid Arthritis.
What is the current status of trial NCT01055899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT01055899?
The interventions under investigation include: REGN88 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01055899?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.